This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferrario, A. Articles by Gomer, C. J. Search for Related Content PubMed PubMed Citation Articles by Ferrario, A. Articles by Gomer, C. J.

Celecoxib and NS-398 Enhance Photodynamic Therapy by Increasing In vitro Apoptosis and Decreasing In vivo Inflammatory and Angiogenic Factors

¹ The Saban Research Institute, Children's Hospital Los Angeles and ² Departments of Pediatrics and Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, California

Requests for reprints: Charles J. Gomer, Children's Hospital Los Angeles, Mail Stop 67, 4650 Sunset Boulevard, Los Angeles, CA 90027. Phone: 323-669-2335; Fax: 323-669-0742; E-mail: cgomer{at}chla.usc.edu.

Photodynamic therapy (PDT) elicits both apoptotic and necrotic responses within treated tumors and produces microvascular injury leading to inflammation and hypoxia. PDT also induces expression of angiogenic and survival molecules including vascular endothelial growth factor, cyclooxygenase-2 (COX-2), and matrix metalloproteinases. Adjunctive administration of inhibitors to these molecules improves PDT responsiveness. In the current study, we examined how the combination of PDT and COX-2 inhibitors improve treatment responsiveness. Photofrin-mediated PDT combined with either celecoxib or NS-398 increased cytotoxicity and apoptosis in mouse BA mammary carcinoma cells. Immunoblot analysis of protein extracts from PDT-treated cells also showed poly(ADP-ribose) polymerase cleavage and Bcl-2 degradation, which were further enhanced following combined therapy. Tumor-bearing mice treated with PDT and either celecoxib or NS-398 exhibited significant improvement in long-term tumor-free survival when compared with PDT or COX-2 inhibitor treatments alone. The combined procedures did not increase in vivo tumor-associated apoptosis. Administration of celecoxib or NS-398 attenuated tissue levels of prostaglandin E₂ and vascular endothelial growth factor induced by PDT in treated tumors and also decreased the expression of proinflammatory mediators interleukin-1ß and tumor necrosis factor-. Increased tumor levels of the antiinflammatory cytokine, interleukin 10, were also observed following combined treatment. This study documents for the first time that adjunctive use of celecoxib enhances PDT-mediated tumoricidal action in an in vivo tumor model. Our results also show that administration of COX-2 inhibitors enhance in vitro photosensitization by increasing apoptosis and improve in vivo PDT responsiveness by decreasing expression of angiogenic and inflammatory molecules.

This article has been cited by other articles:

				Y. Nakagishi, Y. Morimoto, M. Fujita, N. Morimoto, Y. Ozeki, T. Maehara, and M. Kikuchi Photodynamic Therapy for Airway Stenosis in Rabbit Models Chest, January 1, 2008; 133(1): 123 - 130. [Abstract] [Full Text] [PDF]

				A. Ferrario, N. Rucker, S. Wong, M. Luna, and C. J. Gomer Survivin, a Member of the Inhibitor of Apoptosis Family, Is Induced by Photodynamic Therapy and Is a Target for Improving Treatment Response Cancer Res., May 15, 2007; 67(10): 4989 - 4995. [Abstract] [Full Text] [PDF]

				M. Triesscheijn, P. Baas, J. H. M. Schellens, and F. A. Stewart Photodynamic Therapy in Oncology Oncologist, October 1, 2006; 11(9): 1034 - 1044. [Abstract] [Full Text] [PDF]

				N. Solban, S. K. Pal, S. K. Alok, C. K. Sung, and T. Hasan Mechanistic Investigation and Implications of Photodynamic Therapy Induction of Vascular Endothelial Growth Factor in Prostate Cancer Cancer Res., June 1, 2006; 66(11): 5633 - 5640. [Abstract] [Full Text] [PDF]